Law & Regulation
John Oliver Covers Psychedelics on Last Week Tonight
The article John Oliver Covers Psychedelics on Last Week Tonight was originally published on Microdose.
Emmy-award winning talk show host John Oliver…
The article John Oliver Covers Psychedelics on Last Week Tonight was originally published on Microdose.
Emmy-award winning talk show host John Oliver has devoted his entire segment to psychedelic therapy.
Combining long-form journalism and satirical comedy, John Oliver’s Last Week Tonight is known for its in-depth looks at important social issues. They’ve won several Emmys for this kind of work, which makes their recent focus on psychedelic therapy big news for advocates and enthusiasts hoping to educate the public about the potential of psychedelics.
The show covered a range of psychedelic topics, from the history of psychedelic research, the War on Drugs, the current renaissance and its impressive trial results, stories of patient healing, and even patent issues.
This was another important cultural milestone in destigmatizing psychedelics to mainstream audiences.
See below for the full segment.
For more on celebrities on psychedelics, check out Celebrity Psychedelic Update
research psychedelics psychedelic-
Law & Regulation1 week ago
Relmada loses another $21.8M, makes progress with clinical trials
-
Psychedelics6 days ago
BetterLife Obtains Excellent Animal Cardiopulmonary Safety Data for Oral BETR-001
-
Psychedelics5 days ago
atai Life Sciences Reports First Quarter 2024 Financial Results and Corporate Updates
-
Law & Regulation1 week ago
AbbVie, Gilgamesh Pharmaceuticals enter psychiatric drug deal
-
Psychedelics6 days ago
Cybin to Participate in the Alliance Global Partners Healthcare Company Showcase
-
Psychedelics6 days ago
Optimi Health Receives Certificate of Analysis For MDMA 40mg and 60mg GMP Capsules
-
Law & Regulation5 days ago
FDA nod fuels Filament’s psychedelics push, but cash running short
-
Psychedelics6 days ago
Silo Pharma to Participate in FDA Meeting Exploring Emerging Therapeutic Interest in Ketamine